You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
騰盛博藥(02137.HK):長效新冠中和抗體與單抗聯合療法研究獲積極數據
阿思達克 06-10 09:37
騰盛博藥(02137.HK)宣布,旗下控股公司騰盛華創醫藥技術(北京)在中國開展的長效新冠中和抗體安巴韋單抗,和羅米司韋單抗聯合療法的隨機、單盲臨床研究(NCT04787211),近日獲得積極數據, 研究結果顯示,該聯合療法在中國入組的重症和非重症SARS-CoV-2感染者中均表現出良好的安全性及耐受性,未報道與研究藥物相關的嚴重不良事件、輸液反應、及由於不良事件導致的給藥終止或減量。 公司總裁兼大中華區總經理、騰盛華創首席執行官羅永慶表示,目前全國已有20個省市醫療保障局陸續將該聯合療法納入本地醫保基金支付範圍,並且已收到超過20個省市衛健委等抗疫機構或部門、逾百家醫療機構和商業公司的採購意向和儲備需求,將積極推進相關生產及供應的準備工作。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account